Novavax Sees Advantage of Scale on Low-Dose Covid-19 Vaccine

July 21, 2020, 3:27 PM

Novavax says a 5 microgram dosage is expected to be the go-forward clinical dose as the biotech races to develop an effective vaccine for the pandemic.

  • The company is testing 5 and 25 microgram doses in an early stage study; results are expected in July
  • Novavax’s insect-cell technology and the 5 microgram dose can be scaled up easily, R&D president Gregory Glenn said, speaking at the second ISV Covid-19 Vaccines Virtual Congress
  • NVAX has $1.6 billion in funding from the U.S. government as well as backing from CEPI
  • Company is on track for for 100m doses to U.S. by ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.